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Abstract Studies have demonstrated that changes in
DNA methylation of cancer related genes can be an ele-
mentary process accounting for ovarian tumorigenesis.
Therefore, we evaluated the possible association of single
nucleotide polymorphisms (SNPs) of DNA methyltrans-
ferases (DNMTs) genes, including DNMT1, DNMT3B, and
DNMT3A, with ovarian cancer development in the Polish
population. Using PCR–RFLP and HRM analyses, we
studied the prevalence of the DNMT1 rs8101626,
rs2228611 and rs759920, DNMT3A rs2289195, 7590760,
rs13401241, rs749131 and rs1550117, and DNMT3B
rs1569686, rs2424913 and rs2424932 SNPs in patients
with ovarian cancer (n = 159) and controls (n = 180). The
lowest p values of the trend test were observed for the
DNMT1 rs2228611 and rs759920 SNPs in patients with
ovarian cancer (ptrend = 0.0118 and ptrend = 0.0173,
respectively). Moreover, we observed, in the recessive
inheritance model, that the DNMT1 rs2228611 and
rs759920 SNPs are associated with an increased risk of
ovarian cancer development [OR 1.836 (1.143–2.949),
p = 0.0114, pcorr = 0.0342, and OR 1.932 (1.185–3.152),
p = 0.0078, pcor=0.0234, respectively]. However, none of
other nine studied SNPs displayed significant contribution
to the development of ovarian cancer. Furthermore, hap-
lotype and multifactor dimensionality reduction analysis of
the studied DNMT1, DNMT3B, and DNMT3A polymor-
phisms did not reveal either SNP combinations or gene
interactions to be associated with the risk of ovarian cancer
development. Our results may suggest that DNMT1 vari-
ants may be risk factors of ovarian cancer.
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Introduction
Ovarian cancer includes any malignant growth that may
develop in disparate parts of the ovary; however, the
majority of ovarian malignancies arise from the ovarian
epithelium [1]. This type of cancer usually exhibits vague
symptoms and is the one of the most lethal gynecological
cancers in women in the United States and Europe [2].
Although ovarian cancer has been intensively studied, the
underlying cause of this malignant disease remains unde-
termined [1, 3]. There is a lot of evidence that shows a
reduced risk for ovarian cancer in women who use oral
contraceptives, have greater parity, or breastfed long-term
[3]. Known risk factors of ovarian cancer include infertil-
ity, early age of menarche, late age of menopause,
inflammation, some environmental factors, and genetic
background [3]. The known genetic factors encompass a
few high-penetrance genes (e.g., BRCA1) and numerous
moderate and low-penetrance ovarian cancer susceptibility
genes [3]. However, these factors alone are not sufficient
for ovarian tumorigenesis, which indicates that attention
must be paid to the role of epigenetic status changes during
ovarian carcinogenesis [4, 5].
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The term epigenetics describes the reversible regulation
of gene expression that does not occur due to changes in
the DNA sequence [6, 7]. Epigenetic traits include DNA
methylation, covalent modification of histones, and
expression status of genes modulated by lRNA [6, 7].
DNA methylation in mammalian cells is typically
restricted to covalent modification, in which a methyl
group is added to a cytosine located in CpG dinucleotides
in the genomic DNA [6]. CpG dinucleotides are frequently
situated in rich CpG genomic sites designated as CpG
islands, which are found in approximately half of all genes
in humans [8]. Hypomethylation of regulatory DNA
sequences increases the expression of proto-oncogenes and
genes encoding proteins involved in genomic instability
and malignant cell growth and metastasis [6, 9]. By con-
trast, hypermethylation of the promoter regions of tumor
suppressor genes (TSGs) causes the transcriptional silenc-
ing of TSGs [6, 9].
There are three types of enzymatically active DNA
methyltransferases (DNMTs), designated DNMT1,
DNMT3A, and DNMT3B [6, 9]. Abnormal levels of
DNMT1, DNMT3A and DNMT3B contributing to changes
in the expression of cancer related genes have been found in
different types of malignancies [10–13]. The DNMTs levels
can be changed by single nuclear polymorphisms (SNPs)
situated within their genes and which may affect the devel-
opment of various cancers [14, 15]. Therefore, we selected
11 SNPs of DNMT1, DNMT3A and DNMT3B located in
distinct blocks of linkage disequilibrium (LD) according to
HapMap CEU data (http://hapmap.ncbi.nlm.nih.gov/)
(Supplemental Table 1; Supplemental Fig. 1a–c). Further-
more, we aimed to study whether these DNMT1, DNMT3A




The patients include 159 women with histologically rec-
ognized ovarian carcinoma according to the International
Federation of Gynecology and Obstetrics (FIGO). Histo-
pathological classification, including the stage, grade and
tumor type, was performed by an experienced pathologist
(Table 1). The controls included 180 unrelated healthy
female volunteers who were matched by age to the cancer
patients (Table 1). Written informed consent was obtained
from all participating individuals. The procedures of the
study were approved by the Local Ethical Committee of
Poznan´ University of Medical Sciences. All women with
ovarian cancer and controls were Caucasian from the
Wielkopolska area of Poland.
Genotyping
Genomic DNA was isolated from peripheral blood leuco-
cytes by salt extraction. DNA samples were genotyped for the
11 SNPs in DNMT1, DNMT3A and DNMT3B (Supplemental
Table 1; Supplemental Fig. 1a–c.). SNPs were selected with
the use of the genome browsers of the International HapMap
Consortium (http://www.hapmap.org/index.html.en), UCSC
(http://genome.ucsc.edu) and dbSNP database (http://www.
ncbi.nlm.nih.gov/projects/SNP/). SNPs were selected based
on functional significance, location in different LD blocks,
and minor allele frequency (MAF) [0.1 in the Caucasian
population. Genotyping of the DNMT1 rs2228611, rs759920,
DNMT3A rs2289195, rs13401241, rs749131, rs1550117,
DNMT3B rs2424932 SNPs was performed by high resolu-
tion melting curve analysis (HRM) on the LightCycler 480
system (Roche Diagnostics, Mannheim, Germany). Geno-
typing of the DNMT1 rs8101626, DNMT3A rs7590760, and
DNMT3B rs1569686, rs2424913SNPs was conducted by
PCR, followed by the appropriate restriction enzyme diges-
tion (PCR–RFLP) according to the manufacturer’s instruc-
tions (Fermentas, Vilnius, Lithuania). DNA fragments were
separated in 2 % agarose gels and visualized by ethidium
bromide staining. Primer sequences and conditions for HRM
and PCR–RFLP analyses are presented in Supplemental
Table 2. Genotyping quality was evaluated by repeated
genotyping of 10 % randomly selected samples.






Mean age ± SD 55.6 ± 9.6 56.1 ± 8.7
Histological grade
G1 29 (18.2 %)
G2 46 (28.9 %)
G3 44 (27.7 %)
Gx 40 (25.2 %)
Clinical stage
I 44 (27.7 %)
II 35 (22.0 %)
III 54 (34.0 %)
IV 26 (16.3 %)
Histological type
Serous 44 (27.7 %)
Mucinous 27 (17.0 %)
Endometrioid 47 (29.5 %)
Clear cell 18 (11.3 %)
Brenne 3 (1.9 %)
Mixed 10 (6.3 %)
Untyped carcinoma 10 (6.3 %)
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Statistical analysis
For each SNP, the Hardy–Weinberg equilibrium (HWE) was
assessed by Pearson’s goodness-of-fit Chi square (v2) sta-
tistic. The differences in the allele and genotype frequencies
between cases and controls were determined using standard
v2 or Fisher tests. SNPs were tested for association with
ovarian cancer using the Cochran-Armitage trend test. The
odds ratio (OR) and associated 95 % confidence intervals
(95 %CI) were also calculated. The data were analyzed
under recessive and dominant inheritance models. To adjust
for the multiple testing, we employed a correction factor of 3
(0.005/3 = 0.0167) to take into consideration the number of
genes evaluated. This represents a generally accepted cor-
rection strategy; one not as stringent as the Bonferroni cor-
rection, yet still taking the number of totally independent
analyses into account. Pair-wise LD between selected SNPs
was computed as both D0 and r2 values using HaploView 4.0
software (Broad Institute, Cambridge, MA). Haplotype
analysis was performed using the UNPHASED 3.1.5 pro-
gram with the following analysis options: all window sizes,
full model and uncertain haplotype option [16]. Haplotypes
with a frequency below 0.01 were set to zero. The p values for
both global and individual tests of haplotype distribution
between cases and controls were determined. Statistical
significance was assessed using the 1,000-fold permutation
test.
High order gene–gene interactions among all tested
polymorphic loci were studied by the multifactor dimen-
sionality reduction (MDR) approach (MDR version 2.0
beta 5). A detailed explanation on the MDR method has
been described elsewhere [17]. Based on the obtained
testing balanced accuracy and cross-validation consistency
values, the best statistical gene–gene interaction models
were established. A 1,000-fold permutation test was used to
assess the statistical significance of MDR models (MDR
permutation testing module 0.4.9 alpha).
Results
Association of DNMT1, DNMT3A and DNMT3B SNPs
with ovarian cancer development
The frequency of all studied genotypes did not exhibit
deviation from the HWE between all investigated groups
(p [ 0.05). The lowest (0.08) and highest (0.49) MAF
found for the control samples was for DNMT3A rs1550117
and DNMT1 rs2228611 SNPs, respectively (Table 2). The
number of genotypes, OR, and 95 % CI calculations for the
11 studied DNMT1, DNMT3B, and DNMT3A SNPs are
presented in Table 2. The lowest p values of the trend test
were observed for the DNMT1 rs2228611 and rs759920
SNPs in patients with ovarian cancer (ptrend = 0.0118 and
ptrend = 0.0173, respectively) (Table 2). The statistical
significance for multiple testing determined by correction
of genes number was p = 0.0167. Therefore, we observed,
in a recessive inheritance model, that DNMT1 rs2228611
and rs759920 SNPs are associated with increased risk of
ovarian cancer development [OR 1.836 (1.143–2.949),
p = 0.0114, and OR 1.932 (1.185–3.152), p = 0.0078,
respectively] (Table 2). However, none of the other nine
studied DNMT1, DNMT3B and DNMT3A SNPs exhibited
significant association either in dominant or recessive
inheritance models with ovarian cancer development
(Table 2).
Association of DNMT1, DNMT3B, and DNMT3A
haplotypes with ovarian cancer development
Haplotype analysis of DNMT1, DNMT3B, and DNMT3A
polymorphisms did not reveal SNP combinations associ-
ated with the risk of ovarian cancer development (Table 3).
In patients, the lowest global p = 0.0502 was observed for
haplotypes composed of the DNMT1 rs2228611 and
rs759920 SNPs (Table 3). However, these results were not
statistically significant when permutations were used to
generate empiric p values. The empirical 5 % quintile of
the best p value after 1,000 permutations was 0.002566.
The selected 11 SNPs situated in distinct regions of
DNMT1, DNMT3B, and DNMT3A were either in weak or
strong pairwise LD. This was calculated from the control
samples, and had D0 ranges of 0.934–0.976 for DNMT1
SNPs, 0.109–1.000 for DNMT3A SNPs, and 0.626–0.943
for DNMT3B SNPs (Supplementary Table 3).
MDR analysis of gene–gene interactions
among the studied DNMT1, DNMT3A and DNMT3B
SNPs
Exhaustive MDR analysis evaluating two- to four-loci
combinations of all studied SNPs for each comparison did
not reveal statistical significance in predicting susceptibil-
ity to ovarian cancer development (Table 4). The best
combination of possibly interactive polymorphisms was
observed for rs759920 of DNMT1, rs2289195 and
rs7590760 of DNMT3A and rs2424932 of DNMT3B (test-
ing balanced accuracy = 59.03 %, cross validation con-
sistency of eight out of ten, permutation test p = 0.0940).
Discussion
As with other cancer types, aberrant DNA methylation
encompassing CpG island hypermethylation and global
4896 Mol Biol Rep (2013) 40:4893–4899
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hypomethylation of heterochromatin has been demon-
strated in ovarian cancer [4, 5, 12, 18]. To date, it several
genes have been found to be down-regulated in ovarian
cancer due to their hypermethylation [19–23]. These genes
include classical TSGs and genes encoding cell adhesion
molecules, proapoptotic proteins, and other proteins sup-
porting ovarian tumorigenesis [19–23]. DNA hypomethy-
lation in ovarian cancer has been found in chromosome 1
satellite 2 and long interspersed nuclear element-1 (LINE-1)
repetitive elements [18, 24]. In addition to these findings,
many genes are hypomethylated and overexpressed in this
type of cancer. Among these are genes encoding activators
of the mitogen-activated protein kinases, insulin-like
growth factor-2, and proteins associated with chemoresis-
tance [18, 25–27].
Increased levels of some DNMTs have been observed in
ovarian cancer cell lines and primary ovarian cancerous
tissues as compared to normal ovarian cells [10, 11, 28].
Ahluwalia et al. [10] found significantly higher DNMT1
and DNMT3B mRNA levels in ovarian cancer cells than in
normal ovarian surface epithelial cells. Moreover, Chen
et al. [28] observed significantly elevated DNMT1 and
DNMT3B mRNA levels in primary and recurrent epithelial
ovarian carcinoma compared to normal epithelial ovarian
cells. Recently, Cheng et al. (2011) demonstrated that
DNMT1, but not DNMT3A or DNMT3B, levels were
increased in serous borderline ovarian tumor cells. They
also demonstrated that DNMT1 levels correlated with
E-cadherin promoter methylation [11].
In our study we found that the DNMT1 rs2228611 and
rs759920 SNPs can be risk factors of ovarian cancer in a
Polish population. To date, the DNMT1 rs2228611 SNP has
been associated with sporadic infiltrating ductal breast
carcinoma among Chinese Han women in the Heilongjiang
Province [29]. Moreover, the DNMT1 rs2228611 SNP
modified associations between urinary cadmium and hy-
pomethylation of LINE-1 repeated sequences [30]. In
addition to these findings, the two intronic polymorphisms
rs2241531 and rs4804490 of DNMT1 may be associated
with hepatitis B virus (HBV) clearance and protection from
the development of hepatocellular carcinoma [31].
Our studies did not demonstrate an association of the
DNMT3B rs1569686, rs2424913 and rs2424932 SNPs with
ovarian cancer. To date, the DNMT3B rs2424913 poly-
morphism has been demonstrated to be a risk factor of
lung, breast, and head and neck cancers and age of onset of
hereditary nonpolyposis colorectal cancer (CRC) [32–35].
Furthermore, the DNMT3B rs2424913 SNP may contribute
to reduced methylation of CpG islands of the MYOD and
MLH1 genes in normal colonic mucosa of patients with
CRC, and with increased promoter methylation of TSGs
related to the development of prostate cancer [36, 37].
Another polymorphism of DNMT3B, rs2424909, being in
great LD with rs2424913 has been found to be a genetic
Table 3 Haplotype analysis of the DNMT1, DNMT3A and DNMT3B
gene polymorphisms
Gene SNP combination v2 Global
p value
DNMT1a 2-Marker window
rs8101626 rs2228611 5.6892 0.0582
rs2228611 rs759920 5.9849 0.0502
3-Marker window
rs8101626 rs2228611 rs759920 8.3052 0.0810
DNMT3A 2-Marker window
rs2289195 rs7590760 3.3940 0.3348
rs7590760 rs13401241 2.8982 0.4076
rs13401241 rs749131 6.5006 0.0896
rs749131 rs1550117 0.6357 0.8882
3-Marker window
rs2289195 rs7590760 rs13401241 4.1816 0.7586
rs7590760 rs13401241 rs749131 7.1676 0.3056













rs1569686 rs2424913 4.0008 0.2614
rs2424913 rs2424932 1.3364 0.7205
3-Marker window
rs1569686 rs2424913 rs2424932 8.7324 0.1202
a Empirical 5 % quantile of the best p value 0.002566
Table 4 Results of gene–gene interactions analyzed by MDR
method



















a Significance of accuracy, empirical p value based on 1,000
permutations
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risk factor of gastric cancer, CRCs, and gallbladder carci-
noma [38–40].
It has recently been found that the DNMT3A polymor-
phism rs1550117 alters the promoter activity and risk of
gastric cancer and CRC [14, 15]. However, we did not find
an association of any of the five studied DNMT3A SNPs
with ovarian cancer development. Frequent mutations in
DNMT3A have been demonstrated in human T cell lym-
phoma, myelodysplastic syndromes, as well as myeloid and
monocytic leukemias [41–44]. Moreover, the DNMT3A
intronic polymorphism rs13428812, situated in the same
LD block with our studied rs7590760, has been shown to
contribute to Crohn’s disease [45].
DNMT3A and DNMT3B carry out de novo methylation
[7, 13]. DNMT3A and DNMT3B are involved in imprinting
of germ cells and normal embryonic development [46, 47].
Moreover, DNMT3A contributes to the differentiation of
neural progenitors and hematopoietic stem cells [48, 49].
DNMT1 is responsible for the maintenance of the hemime-
thylated DNA methylation pattern during DNA replication,
and also has a role in gene silencing [13, 50].
Our study may suggest that Polish women bearing either
the DNMT1 rs2228611 or rs759920 SNP may have an
increased risk of ovarian cancer. Neither of these polymor-
phisms is a functional variant, and their association with
ovarian cancer may be due to LD with one or more functional
polymorphisms of DNMT1. Therefore, to confirm the role of
these SNPs in ovarian cancer, this study should be repeated in
a larger and independent cohort, and functional studies of
these SNPs must be conducted. Moreover, a future genome-
wide SNPs genotyping study in our sample collection will
additionally provide more knowledge of the genes contrib-
uting to the onset of this disease.
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